October 19, 2016 / 11:50 AM / in a year

Merck's antiviral drug meets main goal in late-stage trial

(Reuters) - Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.

The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant.

The drug was administered once daily, either in oral tablet or IV formulation, to patients and continued for about 100 days after the transplant.

Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.

Reporting by Shailesh Kuber; Editing by Martina D'Couto

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below